Daré Bioscience Receives About $3.6M Payment Under Existing Grant Agreement With Gates Foundation

Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it has received an approximately $3.6 million payment under an existing grant agreement with the Gates Foundation. This new tranche will primarily support ongoing activities to aid in the identification and development of a novel non-hormonal intravaginal contraceptive, suitable for and acceptable to women in low- and middle-income country (LMIC) settings who need or would prefer to use such a product to avoid an unplanned pregnancy.

This payment represents the next tranche under the up to approximately $10.7 million grant agreement originally announced in November 2024 and reflects Daré's continued achievement of key development and reporting milestones.